Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Top Cited Papers
- 1 June 2014
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (6), 614-629
- https://doi.org/10.1016/s1474-4422(14)70090-0
Abstract
No abstract availableKeywords
This publication has 210 references indexed in Scilit:
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque PathologyArchives of Neurology, 2011
- Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNIActa Neuropathologica, 2011
- Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer DiseaseArchives of Neurology, 2009
- Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer DiseaseArchives of Neurology, 2009
- Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer TypeArchives of Neurology, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- Aβ amyloid and glucose metabolism in three variants of primary progressive aphasiaAnnals of Neurology, 2008